Loading...

BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC Management Changes 8-K Filing

BRDG

BBT

BRIDGEBIO ONCOLOGY THERAPEUTICS INC

(BBOT)

2026 8-K

Management Change

Leadership Changes

Financial Results Report

New Clinical Data

Quarterly Results Report

Business Combination

Asset Acquisitions

Business Combination

Business Combination

Business Combination

Director Appointment

External Links:

On March 24, 2026, BridgeBio Oncology Therapeutics, Inc. appointed Dr. Peter Lebowitz as a new board member, increasing the board size to nine. He will receive a stock option for 63,350 shares at an exercise price of $8.72.

AI Assistant

BRIDGEBIO ONCOLOGY THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.